Coeptis Therapeutics (NASDAQ:COEP) Trading Down 7.2%

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP – Get Rating)’s stock price fell 7.2% during trading on Wednesday . The stock traded as low as $1.78 and last traded at $1.84. 49,878 shares were traded during mid-day trading, a decline of 29% from the average session volume of 70,441 shares. The stock had previously closed at $1.98.

Wall Street Analyst Weigh In

Separately, EF Hutton Acquisition Co. I assumed coverage on shares of Coeptis Therapeutics in a report on Monday, December 12th. They issued a “buy” rating and a $6.00 price target on the stock.

Coeptis Therapeutics Stock Performance

The firm has a 50 day moving average price of $1.98. The company has a current ratio of 1.71, a quick ratio of 1.71 and a debt-to-equity ratio of 0.02.

Coeptis Therapeutics Company Profile

(Get Rating)

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies.